该论文来源于网络，本站转载的论文均是优质论文，供学习和研究使用，文中立场与本网站无关，版权和著作权归原作者所有，如有不愿意被转载的情况，请通知我们删除已转载的信息，如果需要分享，请保留本段说明。 [摘要] 目的 探討术前新辅助化疗联合洛铂术中腹腔灌注化疗对晚期卵巢癌患者血清血管内皮生长因子（VEGF）、人附睾蛋白4（HE4）水平及预后的影响。 方法 选取我院自2014年6月～2016年7月收治的80例晚期卵巢癌患者，按随机数字表法分为两组，各40例。观察组实施术前新辅助化疗+肿瘤细胞减灭术+洛铂术中腹腔灌注化疗+术后TP方案化疗，对照组实施常规肿瘤细胞减灭术+术后TP方案化疗，比较两组手术情况、短期疗效、血清VEGF与HE4水平变化情况，并随访1、3年生存率。 结果 观察组的手术时间、术中出血量、腹水量及住院时间均少于对照组（P<）;%，%（P<）;治疗后，观察组血清VEGF、HE4水平均较治疗前降低且低于对照组（P<）;观察组3年生存率高于对照组（P<）。 结论 术前新辅助化疗联合洛铂术中腹腔灌注化疗可明显缩短手术时间、减少术中出血量，提升晚期卵巢癌患者短期疗效，且有利于下调血清VEGF、HE4水平，改善预后。 [关键词] 新辅助化疗;腹腔灌注化疗;晚期;卵巢癌;VEGF;HE4 [中图分类号] [文献标识码] A [文章编号] 1673-9701（2020）10-0004-04 [Abstract] Objective To investigate the effect of preoperative neoadjuvant chemotherapy combined with lobaplatin intraperitoneal chemotherapy on serum vascular endothelial growth factor （VEGF） and human epididymis protein 4 （HE4） levels and prognosis in patients with advanced ovarian cancer. Methods Eighty patients with advanced ovarian cancer admitted to our hospital from June 2014 to July 2016 were randomLy divided into two groups， with 40 cases in each group. The observation group underwent preoperative neoadjuvant chemotherapy+cytoreductive surgery+lobaplatin intraperitoneal infusion chemotherapy and postoperative TP regimen， and the control group underwent routine cytoreductive surgery+postoperative TP regimen. The surgical condition， short-term efficacy， serum VEGF and HE4 levels between two groups were compared. And one-year and three-year survival rate was followed up. Results The operation time， intraoperative blood loss， ascites volume and hospitalization time of the observation group were less than those of the control group（P<）. The total effective rate of the observation group was %， which was higher than that（%） of the control group（P<）. Serum VEGF and HE4 l
